Diabetic Macular Edema

Katherine Talcott, MD, discuss the impact of intravitreal injections on intraocular pressure, emphasizing monitoring and patient safety in treatment.

Christina Y. Weng, MD, breaks down emerging gene therapy programs poised to change how retina specialists treat chronic eye disease.

The FDA identified no issues with the safety or efficacy of aflibercept 8 mg in any of its already approved dosing regimens or indications.

If approved, aflibercept 8 mg would mark the first RVO treatment indicated for up to every 8-week dosing, halving the injection frequency of other anti-VEGF options.

Tailor discusses the future of AI in ophthalmology and beyond, and some of the challenges it may bring.

Our Q1 2025 recap for ophthalmology spotlights 5 regulatory updates, 5 key trial announcements, and two episodes of our flagship ophthalmology podcast.

Aflibercept 8 mg produced the same or better results compared to other anti-VEGFs while requiring fewer injections.

Used as a biomarker across many specialties, the platelet-to-neutrophil ratio may soon enter ophthalmology for diabetic macular edema prediction.

McCulley examines the latest updates on GLP-1 receptor agonists relevant for ophthalmologists and patients with ophthalmic diseases at TOA 2025.

Study finds positive association between weight-adjusted waist index and risk of age-related macular degeneration in adults aged 40 or over.

Veeral Sheth, MD, is joined by the CEO of Oculis to discuss the company's ophthalmic pipeline, including OCS-01 for DME and OCS-05 for acute optic neuritis.

The February 2025 month in review covers 7 key pipeline updates in ophthalmology, including regulatory approvals, label expansions, and topline trial results.

The January 2025 ophthalmology month in review highlights the latest from the FDA, key updates to the ophthalmic pipeline, and the latest episode of New Insight.

Both doses of DURAVYU extended the time to the first supplemental injection versus aflibercept control in the Phase 2 VERONA trial.

The FDA’s approval marks the second indication for Genentech's refillable ocular implant in addition to wet age-related macular degeneration.

4D-150 shows promising efficacy and safety in DME as FDA greenlights Phase 3 trial for Biologics License Application submission.

Aflibercept 8 mg achieves non-inferior vision gains with an every 8-week dosing interval in patients with macular edema following retina vein occlusion.

A look back at some of our top coverage in ophthalmology from 2024, including pipeline news and FDA approvals.

Glycemic control continues to be a major risk factor for diabetic retinopathy, while overweight, obesity, and hypertension are growing in prevalence.

At AAO 2024, Wykoff discussed first-time extended results from AMARONE showing Restoret’s effectiveness in improving outcomes for patients with DME and nAMD.

At AAO 2024, Garg describes an analysis of the Phase 2/3 PHOTON trial evaluating the effect of DME treatment history on aflibercept 8 mg and 2 mg outcomes.

Endophthalmitis incidence remained similar between face masking and non-face masking groups during anti-VEGF treatment.

A history of anti-VEGF injections for retinal conditions may increase the incidence of complications after cataract surgery.

This September 2024 month in review highlights recent advances in gene therapies and therapies demonstrating the potential for improved vision outcomes.

MYL-1701P showed equivalent efficacy, with comparable safety and immunogenicity, to reference aflibercept in the Phase 3 INSIGHT trial.